MDL-29951 is primarily investigated for its potential therapeutic applications in the field of neuroscience. It acts as a selective antagonist for certain glutamate receptors, particularly those involved in excitatory neurotransmission. This property makes it a candidate for studying and potentially treating neurological disorders such as epilepsy, neurodegenerative diseases, and chronic pain conditions. By modulating glutamate receptor activity, it may help reduce neuronal excitotoxicity, which is implicated in conditions like Alzheimer's disease and stroke. Additionally, its role in receptor inhibition provides a tool for researchers to better understand the mechanisms of glutamate signaling in the brain, aiding in the development of targeted therapies for CNS-related disorders.